Compare GSK plc (GSK) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kyndryl Holdings Inc — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while Kyndryl Holdings Inc trades at $11.9 (market cap $2.58B). The key difference: GSK plc is far larger — about 39.3× Kyndryl Holdings Inc's market cap, and GSK plc pays a 3.49% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| GSK | KD | |
|---|---|---|
Market Cap | $101.34B | $2.58B |
Sector | Health | Technology |
52-Week High | $61.18 | $39.47 |
52-Week Low | $36.20 | $10.59 |
Enterprise Value | $121.95B | $4.92B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Kyndryl (KD) trades at $11.84, up 1.98% today, with a bearish technical signal and mixed earnings. Recent quarters show volatility with two misses, but 2025 marked a return to profitability with $252M net income. Cash flow improved to $236M, though revenue declined to $15.1B. The stock faces headwinds from legal investigations and internal control concerns highlighted in recent news.
Outlook: Attractive valuation metrics (P/E 13.79, EV/EBITDA 3.11) and analyst consensus target of $14.33 suggest 21% upside. Risks include ongoing legal scrutiny, revenue contraction, and high debt levels. Improved cash flow and partnerships with Microsoft/AWS support a cautious bullish case if execution stabilizes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
